Background In 2010, after regulatory review of rosiglitazone licensing, the US Food and Drug Administration (FDA) requested a reevaluation of cardiovascular end points in the RECORD trial.
Identification of suspected clinical end points using prespecified event definitions is critical to event adjudication efforts in multinational clinical trials. 1 The RECORD trial was a randomized, open-label trial comparing rosiglitazone-containing combination therapy for type 2 diabetes with the dual oral combination of metformin and a sulfonylurea. The trial (ClinicalTrials. gov, NCT00379769) was conducted from 2001 to 2008. 2 The results of the RECORD trial, together with other data, were reviewed and discussed in July 2010 by an Advisory Committee of the US Food and Drug Administration (FDA). After the review, the FDA required the sponsor of the RECORD trial, GlaxoSmithKline (GSK), to commission a comprehensive, reevaluation of the cause of deaths and of 2 nonfatal events: myocardial infarction (MI) and stroke. The Duke Clinical Research Institute (DCRI) was selected to conduct the review. Results of the reevaluation are presented separately. 3 This article reports the methods that were developed to perform the reevaluation effort. The key objectives of this effort were to (1) systematically identify all deaths, suspected MIs, and strokes blinded to treatment; (2) derive end-of-follow-up dates; (3) adjudicate all suspected events by original RECORD definitions and by contemporary definitions under development by the FDA (Standardized Data Collection for Cardiovascular Trials Initiative); and (4) report event rates and time-to-event analyses by treatment group.
Methods

Planning
The DCRI coordinated all clinical events classification (CEC) operations for the RECORD reevaluation protocol in collaboration with the sponsor. In the planning phase, leadership from the sponsor, the FDA, and the DCRI discussed critical issues to design the reevaluation effort, particularly the event identification ("triggering") strategy, the need for collection of additional source documents, and additional ascertainment of lost-tofollow-up patients. The original RECORD principal investigator and trial CEC chairman reviewed and commented on the draft protocol for the reevaluation effort.
The DCRI CEC team created and maintained the CEC charter for RECORD reevaluation, as well as the adjudication pages used to capture key data required for the efficient and accurate adjudication and final analysis of end point events. The DCRI CEC charter (online Appendix A) describes the operations followed for identification of suspected events, collection of data and source documents, DCRI reevaluation, and quality control. It also details the organization, roles, and activities of the DCRI CEC group, including the physicians who formed the DCRI CEC Committee.
The DCRI CEC group systematically identified, adjudicated, and classified the following suspected events using prespecified criteria: cause of death, MI, and stroke.
Duke Clinical Research Institute CEC Committee members
The DCRI CEC Committee members were physicians who provided clinical expertise in development of the CEC processes and CEC adjudication forms and participated in adjudication of suspected end points. No sponsor representatives or members of the original RECORD CEC committee served on the DCRI CEC Committee. Members included faculty-level endocrinologists, cardiologists, neurologists, and other physicians with relevant clinical expertise, involvement in clinical research, and prior CEC experience.
All CEC Committee physicians were trained regarding the RECORD reevaluation protocol and event definitions before starting event adjudication. Documented training comprised an overview of the protocol, trial timelines, specific definitions and supporting documentation for each event type, adjudication form instructions, and adjudication timeline expectations.
Identification of suspected events
A comprehensive process to "trigger" all potential death, MI, and stroke events included both automated and manual trigger procedures ( Figure 1 ). This process was designed to systematically identify events from investigator-identified events, case report forms (CRFs), and adverse event (AE), and serious AE (SAE) reporting; to try to mitigate any potential reporting bias
(RECORD was open label); and to ensure that all potential events were identified and reviewed. Vital status in those participants lost to follow-up was ascertained, as detailed below. Medical Dictionary for Regulatory Activities-coded AE and SAE terms in the clinical database were electronically screened to identify potential cardiovascular end points. Determination of which terms would be used to identify cardiovascular end points was made by DCRI clinical and safety experts. Details of the automated procedures and trigger specifications are contained within the RECORD reevaluation CEC trigger specifications (online Appendix B) . Each potential event was tracked throughout the process using a unique identifier.
Manual trigger procedures. The DCRI CEC coordinators manually reviewed all paper documents separately from the output from the automated trigger program. These coordinators had extensive experience in cardiology event reporting and in CEC methodologies. A quality control process was implemented for the manual review (see below).
Source documents and further data collection.
Participant identifiers, treatment assignment, and other glucoselowering agent use were redacted from all data sent to the DCRI CEC, a task performed a priori by GSK. Blinding was checked by DCRI CEC coordinators and assistants before event dossiers were sent to CEC physicians, further redaction being performed if necessary.
The DCRI also accessed the source documents used by the original RECORD CEC (Table I) . For newly identified events, source documents required are listed in Table II . Source documents were requested from investigator sites for both previously adjudicated and new end points, including the former missing documents. When needed by the DCRI CEC, additional information was requested (up to 2 attempts) from sites and locally redacted before submission to the CEC. All new data were identified as such to allow evaluation both with the original and the original plus new data, and thus, after completion of readjudication and database lock, comparisons between original and new adjudication of events. Documents not in English were translated by an outside vendor.
phases. Phase 1 transfer included the raw CRF data sets needed to provide electronic identification of events for referral to the DCRI CEC. DCRI programmers checked and, where necessary, requested further redaction and data retransfer. Phase 2 transfer occurred after completion of DCRI electronic identification of potential events; this transfer included treatment start and stop dates (blinded) and a data set containing the identification numbers for deaths, as originally reported. Phase 3 transfer included treatment information (unblinded); these data were kept firewalled from the clinical team until all DCRI adjudications were completed. The data were placed in a secure folder on the DCRI server, and access was granted only to the unblinded statistical team members responsible for producing the report of readjudicated events.
Event adjudication
The DCRI CEC process is summarized in Figure 2 . The DCRI CEC physicians adjudicated each suspected event identified by the automated or manual trigger procedures described above using prespecified end point criteria based on the preponderance of the evidence, clinical knowledge, and experience. All events were reviewed using the original RECORD end point definitions themselves, reflecting European Society of Cardiology recommendations, and-by request of the FDA-were also reviewed using new FDA end point definitions that resulted from the Standardized Data Collection for Cardiovascular Trials Initiative. 4, 5 Online Appendix C displays the original RECORD end point definitions, and online Appendix D provides the new FDA definitions. The key differences between the original RECORD end point definitions and the new FDA definitions are shown in Table III. Potential events triggered from an AE term only, with no hospitalization or source documentation present, were reviewed by a single clinician (DCRI CEC coordinator or physician) to confirm whether there was a potential event. If that was the case, the event dossier and data were forwarded for review by physicians, including possible stroke events by a neurologist. Events were allocated to 2 physicians acting independently, and for MI, a separate pair of physicians were used for original and FDA definitions. If one reviewer requested and received additional information, it was also given to the other reviewer.
Where the 2 reviewers agreed in adjudication of the suspected event, the end point classification was deemed complete. Otherwise, the event was referred to an adjudication committee. At least 3 faculty physicians were required for this, with a decision made by consensus. The basis of the decision was documented. If further information was requested, the event was reviewed at a further meeting.
For suspected strokes, phase 1 review required 2 neurologists or, alternatively, review by the CEC committee, which then had to include a neurologist ( Figure 2 ).
Quality control of the evaluation process
A random sample of adjudicated events was re-reviewed by a committee of at least 3 DCRI CEC faculty physicians who were blind to the initial decision. The quality control plan was based on a 5% random sample of adjudicated events (but greater than the square root of the number of events plus 1) generated by the DCRI CEC statistician. The sample was weighted toward the earlier part of the adjudication process for mortality events.
A "major" discrepancy was declared when there was disagreement on whether a defined event had occurred. A "minor" discrepancy involved disagreement on the date, time, type, or evidence. Major discrepancies were allowed to update the adjudication database but only after further committee review and discussion with the CEC principal investigator. Events with a minor discrepancy were not re-reviewed, and the results remained unchanged in the database.
Quality control of the manual trigger program
A random sample of the documents that were screened during the manual trigger procedures were rescreened by a physician using the same documents originally screened by the coordinators. The sample size was 5% of the participants screened and not triggered for an end point event, plus 5% of all other manual triggers.
Statistical analysis
Details of the statistical analysis plan (SAP) are described in the online Appendices E and F. In brief, the first phase of the event reevaluation process entailed adjudication of all-cause and cardiovascular (or unknown cause) mortality, and comparative analyses were completed. In the second phase, MIs and strokes were adjudicated, and analyses of these and major adverse cardiac events (earliest of MI, stroke, or cardiovascular death) were conducted. All analyses were performed for both original RECORD CEC and new FDA definitions.
For each end point, the hazard ratio (HR; rosiglitazone compared with metformin/sulfonylurea) and 95% confidence intervals were calculated using Cox proportional hazard modeling, stratified by background therapy (metformin or sulfonylurea). The HRs (95% CIs) were also calculated for each background therapy group, and a test for interaction was conducted at the P b .10 level. This statistical approach was similar to that used in the original RECORD study. Event rates (per 100 years) were reported for each end point.
Mortality and major adverse cardiac events
A DCRI statistician (G.H.) participated in the development of the event trigger rules, adjudication forms, and query rules; drafted the SAP; created the analysis data set; wrote the reporting specifications; and oversaw the statistical programming and quality control. She remained blinded to treatment allocation throughout phases 1 and 2 (see above). A DCRI faculty/reviewing statistician (R.B.) who provided consultation on these statistical activities also remained so blinded. These personnel controlled all access to treatment assignments or use of other glucose-lowering medications.
Two DCRI statisticians were also unblinded to review the mortality event reevaluation results once completed.
Blinding
Formal procedures were identified to ensure blinding of the randomly assigned treatment group until knowledge of the Clinical events classification process flow. MD, CEC Committee physician; QC, quality control. treatment assignment was required or the reevaluation effort was completed. The principal investigator for the reevaluation (K.W.M.) remained blinded until statistical analyses were complete.
The DCRI faculty lead for the first phase reevaluation of mortality (L.K.N.) was unblinded to review these reevaluation results once complete. The mortality report was reviewed by 9 GSK personnel who were firewalled from the reevaluation process to check the accuracy of text citing the original RECORD trial or describing steps taken by GSK to obtain additional follow-up information. This group was also responsible for fulfilling the study sponsor's regulatory submission requirements and informed the GSK Corporate Executive Team about the completion of the first phase and apprised them of the results.
The DCRI faculty lead for the second phase reevaluation of major adverse cardiac events (R.D.L.) was unblinded after the database lock to review the results of reevaluation of major adverse cardiac events, MI, and stroke and to help prepare the study report of the second phase.
Role of the funding source
The role of the sponsor (GSK, King of Prussia, PA) in the conduct of the study has been published previously. 2 Funding for the reascertainment and reevaluation was provided to DCRI. The sponsor and members of the RECORD Steering Committee reviewed and commented on the protocol and procedures of reevaluation before any reascertainment activity but did not have any further role until reevaluation was finalized. It was planned that the original RECORD leadership and DCRI leadership would review the results of the reevaluation effort and review discrepant adjudications as a learning activity. Both DCRI and the RECORD Steering Committee representatives made the decision to publish the findings and have written the manuscript jointly. The manuscript was reviewed by sponsor representatives for accuracy.
Results
Myocardial infarction/stroke event triggers
A total of 2,597 MI/stroke triggers were identified, 2,101 MIs and 496 strokes. The automatic trigger program identified 2,052 MIs and 468 strokes, and manual document review identified 49 MIs and 28 strokes. Of the 2,597 events triggered, there were 4 for which there was no evidence in the medical records that an event occurred, whereas 697 duplicate triggers for another event were set to linked status. (ie, if more than 1 trigger fired for the same event, only 1 trigger was adjudicated, and the other triggers were listed at the bottom of the CEC adjudication forms as "supplemental Death CV death will include death after heart failure, death after acute MI, sudden death, and death due to acute vascular events.
CV death includes death resulting from an acute MI, sudden cardiac death, death due to heart failure, death due to stroke, and death due to other CV causes. Death due to acute vascular events is defined as death due to aortic dissection, aortic aneurysm, pulmonary embolism, stroke, or any other vascular cause.
Death due to other CV causes refers to a CV death not included in above categories (eg, dysrhythmia, pulmonary embolism, CV intervention, aortic aneurysm rupture, or peripheral arterial disease). Deaths with an unknown cause will be counted as CV death for the primary end point analysis.
Mortal complications from cardiac surgery or nonsurgical revascularization will be classified as CV death. trigger repeats"). There were, therefore, only 1,896 unique events; these 1,896 MI/stroke event triggers were then identified for adjudication. Thus, there were no duplicate events, but just duplicated triggers for other events, which were evaluated and resolved by the DCRI group before adjudication.
MI
Myocardial infarction/stroke queries
For the suspected MI and stroke events, 70 CEC queries requesting additional information from the site investigators or coordinators were issued with the following results: 31 queries were closed with no response from the site, 20 queries were closed with a response that no additional data were available, and 19 queries were closed with additional data being received. Of these 19, 2 resulted in changed MI adjudication results (yes/no), one in each direction.
Death event triggers
A total of 427 death event triggers were identified. The automatic trigger program identified 396 deaths, and 31 deaths were identified manually. Of the total, 100 triggers were not adjudicated because there was no evidence on checking the medical record that a death had occurred.
Death queries
A total of 127 CEC queries were issued for additional information to follow up on death events classified as "unknown" and "insufficient information." The queries for these 127 patients resulted in 43 with no response from the site, 61 with a response that no additional data were available, and 23 closed with additional data received from the site. Of these 23 queries, 16 deaths were re-reviewed with no change to the adjudication result, and 7 events were re-reviewed with a change to the adjudication result from unknown to a known cause of death.
Quality control findings
A medical review of 100 randomly selected stroke and MI events was performed blind to treatment assignment and original DCRI CEC adjudication outcome. In 93 events, there was no discrepancy in the determination. There was 1 major discrepancy (change of event classification), 2 discrepancies involving Q-wave classification, and 4 other discrepancies involving event date/ time. A medical review of 25 randomly selected death events were also performed as part of the quality control process. There were 2 major discrepancies on cause of death. Both of them occurred in the first 10 quality control death cases and were originally called sudden cardiac deaths; after the quality control review, they were changed to unknown cause in the database. There were no major discrepancies in the subsequent 15 quality control death cases.
Discussion
Diabetes is an epidemic disease that is expected to affect around 450 million people by 2030, with a substantial increase in incidence in developing countries. [6] [7] [8] The direct health care costs of diabetes range from 2.5% to 15% of annual health care budgets. 9 Although intensive glucose control has been associated with lower rates of MI, it also has been associated with higher mortality rates, including cardiovascular mortality. 10 The available data on risk of myocardial ischemia among patients using rosiglitazone are inconclusive. A metaanalysis of 42 short-term clinical studies (most of which compared rosiglitazone with placebo), including 14,237 patients with a mean duration follow-up of 6 months, suggested an association between rosiglitazone use and an increased risk of myocardial ischemic events. 12 Other studies, including the RECORD trial, comparing rosiglitazone with other oral diabetes medications or placebo (total patients around 14,000, with a mean follow-up of 41 months) have not shown the same risk. 2, 13, 14 Several examples of treatment that improve surrogate end points, such as decreasing glycated hemoglobin in patients with diabetes or increasing hemoglobin value in patients with cancer or renal disease, have subsequently been found to cause an increase in important clinical events, including mortality. 5, [15] [16] [17] [18] [19] Indeed, the RECORD trial confirmed the increased rate of distal fractures in women identified by ADOPT in 2008 20 and quantified the rate of increase of hospitalizations for heart failure. However, the primary end point was cardiovascular safety of rosiglitazone, defined as all cardiovascular hospitalizations. Participants were followed up for 5.5 years, on average, in a comparative (vs metformin or sulfonylurea) design. There were several secondary end points including a major cardiovascular event composite (cardiovascular death, MI, or stroke). All cardiovascular end points were determined by a team of cardiologists/stroke physician/diabetologists blinded to treatment assignment. The study reported no difference in the occurrence of the primary end point in the rosiglitazone group compared with combined use of metformin and a sulfonylurea. Therefore, the DCRI RECORD CEC reevaluation was undertaken to attempt to address the regulatory, research, and clinical communities' concerns about the efficacy and safety of rosiglitazone in people with type 2 diabetes. This effort, which had the collaboration of the original RECORD trial leadership, sponsor (GSK), the FDA, and the DCRI, included an intense, and comprehensive process to identify all possible events that might have occurred in the original RECORD trial. The DCRI CEC group used predefined criteria to review all suspected incidences of deaths (cardiovascular and noncardiovascular), MI, or stroke and to judge whether a death, MI, or stroke had actually occurred. For patients deemed to have died or had an MI or stroke, the CEC identified the date of the event. The end of follow-up for patients who did not experience cardiovascular death, MI, or stroke was considered to be the last date at which vital signs were recorded on the CRF.
Clinical events classification efforts are becoming more common as a result of interactions between the FDA and pharmaceutical companies. For the RECORD reevaluation, extensive efforts were made to obtain additional source documentation for selected events as well as vital status for patients who did not complete the study follow-up. These efforts were challenged by multiple factors including closure of some research sites, lack of current institutional review board approval, national regulations preventing additional follow-up, unavailability of principal investigators and coordinators, and the long elapsed time since the initial trial had completed. Thus, many queries that were sent to the sites could not be answered, nor could new information be obtained from the sites to allow for the addition of new events to the analysis. It is uncertain whether additional source document collection would have resulted in additional events being identified. Researchers may consider this information when planning retrospective efforts to collect additional clinical data in previously completed trials or drug development programs.
The analysis of the primary end point using both the original RECORD end point definitions and the new draft FDA end point definitions may add relevant information to rosiglitazone's profile, allow interpretation of the RECORD trial with a contemporary set of clinical end point definitions, and provide insights about the value of the revised definitions compared with historical standards. There is consensus about the need for standardized definitions to allow comparison of event rates across trials and over time, but the specific criteria in the definitions are often still debated.
Conclusions
A comprehensive, systematic, and blinded, program was designed to reevaluate event ascertainment and adjudication in the RECORD trial at the request of the FDA. Procedures included rigorous blinding of randomized treatment assignment, collection of additional information about patients previously lost to follow-up, and systematic identification of all deaths and suspected MI and stroke events using the raw data set. These procedures used in this unique situation were consistent with other common approaches in the field, were enhanced to address the FDA concerns about the original RECORD trial results, and could be considered by clinical trialists designing event readjudication protocols for drug development programs that have been completed. Administration (FDA) required the sponsor of the RECORD study, GlaxoSmithKline (GSK), to commission a comprehensive independent readjudication, at the patient record level; to determine the cause of all deaths; and to adjudicate all suspected nonfatal myocardial infarction (MI) and all suspected nonfatal stroke end points of the study.
Appendix A. Clinical Events Classification Charter
Representatives from the FDA and GSK have previously agreed that the readjudication effort will have 2 phases. The first phase will include the readjudication of all deaths, and those results will be analyzed and submitted to the FDA. The second phase will include the readjudication of the nonfatal MI and stroke events. The second phase will begin before completion of the first phase.
The Duke Clinical Research Institute (DCRI) has been asked by GSK to conduct the independent review and submit results to the FDA for comparison with those based on the adjudication outcomes from the original RECORD Clinical Endpoints Committee.
The primary objective of the readjudication is to address some of the critical FDA concerns about the RECORD trial that have been detailed. (FDA briefing document: http:// www.fda.gov/downloads/AdvisoryCommittees/ CommitteesMeetingMaterials/Drugs/Endocrinologicand MetabolicDrugsAdvisoryCommittee/UCM218493.pdf). 22 Key specific objectives include the following:
• Systematic identification of all deaths, all suspected MIs, and all suspected stroke events using all available data sources by reviewers who are blinded to patient treatment assignment The DCRI RECORD CEC group is responsible for the conduct of the CEC operations for the RECORD Readjudication Protocol, in collaboration with the sponsor, GSK. The DCRI CEC group creates and maintains the CEC Charter and will develop the event adjudication pages to capture key data required for the efficient and accurate adjudication and final analysis of the following suspected events:
RECORD CEC group organization
The RECORD CEC group will systematically identify, adjudicate, and classify suspected events while blinded to treatment assignment as well as all glucose-lowering agents. All subject personal identifiers, treatment assignment, and glucose-lowering agents will be redacted from the subject data, including all source documents. RECORD subject study numbers will not be redacted. The RECORD CEC group will develop trial-specific processes for the identification of suspected end point Documentation of the required qualifications for the selected RECORD CEC physicians will be maintained at the DCRI in the form of current curricula vitae. Membership in the RECORD CEC Committee is for the duration of the study unless the member is deemed by the RECORD CEC chairperson in conjunction with the principal investigator to be unable to fulfill his/her responsibilities.
All RECORD CEC physicians will undergo training regarding the RECORD study before starting event adjudication. Training will be conducted by the RECORD CEC chairperson and/or RECORD CEC coordinators. Training material is produced and provided to the CEC physicians. This consists of an overview of the protocol, trial timelines, a detailed list and definition of each event to be adjudicated, supporting source documentation for each event, adjudication form completion instructions, and adjudication timeline expectations. Training documentation for each reviewer is maintained by the CEC.
3.2. DCRI RECORD CEC chairperson/director. One DCRI faculty member will be appointed as the RECORD CEC chairperson. The specific responsibilities of the CEC chairperson include the following:
• Preside over RECORD CEC readjudication conference calls and meetings or delegate to an appropriate designee from the CEC • Ensure that ongoing QC reviews of readjudicated events are conducted and that the readjudication process is being conducted according to the RECORD CEC readjudication Charter and that end point criteria are being accurately applied 
Identification of suspected events.
A comprehensive process to identify or "trigger" all suspected end point events will be developed. Automated and manual procedures will be implemented. This process is designed to systematically identify the events from all data sources in which events may have been reported by the site investigators. This approach will be used to mitigate any potential reporting bias and to ensure that all potential events are identified and reviewed. 4.1.1. Automated trigger program. The automated procedures will include a computer program (trigger program) that includes, but is not limited to, the following:
• Screening of all Adverse Experience (AE) and Serious Adverse Experience (SAE) forms from the CRF data fields in the GSK RECORD data sets.
• Prespecified Medical Dictionary for Regulatory
Activities coded terms will be used. The coded preferred terms were reviewed by clinical, CEC, and safety experts to identify terms that would potentially be indicative of an end point with a low threshold. A similar approach has been used in previous readjudication efforts.
• Death Form (Form D) when present in the database.
Initial trigger specifications will be defined at the start of the program; however, they may be modified during the course of the readjudication process, as needed. Any modifications will be documented and a rationale provided. The trigger specifications will be detailed in a separate document, titled RECORD Readjudication Trigger Specifications.
Manual trigger procedures.
The RECORD CEC coordinators will perform a manual review of paper documents as well as reviewing the output from the automated trigger program. The CEC coordinators reviewing the paper documents have extensive experience in cardiology event reporting and CEC methodologies. A quality control (QC) process will be implemented for the manual review. Paper sources that the CEC coordinators will review to identify potential end points include, but are not limited to, the following:
• The unscheduled visit form (all visits) that inquires about hospitalizations (Hospitalization or Accident and Emergency Department Visit End Point Form) will be used to screen for potential end points. Cardiovascular and noncardiovascular reasons for admission will be assessed for review for potential MI and stroke end points. The following is a list of reasons that have been used in prior programs: heart failure, MI, acute coronary syndrome, unstable angina/cardiac chest pain, atrial fibrillation/flutter, other supraventricular, tachyarrhythmia, ventricular dysrhythmia, acute renal failure, acute or chronic renal failure, renal disease, other renal, stroke, transient ischemic attack, hypertension, hypotension, syncope/pre/syncope, peripheral arterial embolus, deep venous thrombosis, pulmonary embolus, vascular procedure, chronic obstructive pulmonary disease, and pneumonia.
• Source documents used as part of the original RECORD CEC adjudication process and any additional source documents collected as part of the readjudication activities (discharge summaries, progress notes, pertinent lab values, and physician narratives) • Investigator verbatim terms • All SAE and AE forms • All cases that were sent to the original RECORD CEC; this would include end points that were adjudicated as non-end points and all cases that were later deleted by the investigator • All Death End Point Forms • All available 12-lead ECG tracings for subjects who were included in the RECORD ECG substudy and triggered for a potential MI event per automated trigger program • All available 12-lead ECG tracings for subjects who were included in the RECORD ECG substudy and were determined to have a new Q-wave MI per substudy analysis
Both SAEs and AEs that were deleted by RECORD investigators will be identified from the audit trail of the study's electronic data sets, which GSK provided to DCRI. The electronic data sets will be sent to the DCRI before the event packet files, which include data from the CRF and source documents.
Each CEC trigger will have a unique identifier assigned to it to track each event through the CEC process.
Specific Manual Trigger Procedures will be documented in a separate document, titled RECORD Readjudication Trigger Specifications.
4.2. Collection of data. All data sent to the DCRI RECORD CEC group will have subject personal identifiers, treatment assignment, and glucose-lowering agents redacted. This will include electronic data sets as well as source documents and paper CRFs. GlaxoSmithKline is responsible for the redacting before delivery of data or documents to the DCRI. The RECORD CEC coordinators, clinical data assistant, and clinical trial assistants will ensure that information has been blinded or redacted done before sending event packets to the CEC physicians. If, during the course of DCRI activities, it is noted that information that should have been redacted was not, then the DCRI RECORD CEC coordinators, clinical data assistant, and/or clinical trial assistants will redact the information, document the event, and notify GSK. Event packets that will include the contents that were used in the original adjudication process will be provided to the CEC.
When additional information is needed to aid in the CEC adjudication, sites will be contacted directly by DCRI CEC for supporting documentation or data clarification to help render an adjudicated result. Duke Clinical Research Institute CEC will generate a request for source documents for end points that were previously adjudicated as well as for all new end points. Duke Clinical Research Institute CEC will also request any documents from sites that were missing from the previous adjudication process. Requests sent by the DCRI CEC coordinator will also be directly entered in the CEC tracking database. Sites will submit the additional information directly to the DCRI CEC RECORD e-mail inbox. The DCRI CEC coordinator will note that information was obtained using the CEC tracking form. Additional documentation that is added to event packet will be noted as "new information" at the top of the page of the source document and tracked in the CEC tracker so that comparisons between the readjudication results and the original adjudication results will allow analysis of whether additional source documents were used during the readjudication process.
When additional source documentation is needed to support the adjudication for a suspected event, DCRI CEC will make 2 attempts to gain resolution of the request for information from the sites. If additional information is not available for an end point, the site will note that on the request form and that information will be provided in the event packet. If additional information is received after the adjudication has been completed that might affect the adjudication result, the event will be re-reviewed. The CEC adjudication form and database will be subsequently updated to reflect any changes to the initial adjudication. The DCRI will accept documents that are not in English. Duke Clinical Research Institute will contract with an independent vendor for translation services. 4.2.1. Source documents. Duke Clinical Research Institute received from GSK source documents used in event adjudication by the original RECORD Clinical Endpoints Committee. The specific documents that were requested are outlined below:
• Death-for patients who died during the RECORD study:
• Death in hospital:
• Death summary or • Investigator narrative • Autopsy report if available • Death out-of-hospital:
• Narrative of investigator • Autopsy Report if available • Police report/family records/whatever documents could be provided to clarify the circumstances • Hospitalization-a hospital discharge letter, or a narrative about the hospital stay from the investigator • Hospitalization for Acute MI • Hospital discharge summary including the results of the patient's ECG(s) taken during the hospital admission and results of cardiac biomarker laboratory tests.
• If the hospital discharge summary was lacking ECG and enzyme details, a hardcopy of the ECG plus a hardcopy of the cardiac biomarker results were required. If a hard copy of the cardiac biomarker results was not available, the investigator had to complete the MI/Unstable Angina end point form (section Cardiac Biomarkers).
• Hospitalization for Stroke
• Hospital discharge summary with results of a neurologist's investigations provided in the discharge summary. If the discharge summary did not provide sufficient detail, the translated neurological report was requested. If the neuro-216.e4 Lopes et al logical report was not obtainable, the investigator summarized a verbal account from the neurologist in the end point CRF pages for stroke and transient ischemic attack (TIA).
For new events identified by the DCRI RECORD CEC Group, the following source documents are recommended:
• Death events:
• Death summary • Investigator narrative • Autopsy report if available • MI events:
• Hospital discharge summary If all recommended source documents are not present and cannot be obtained from the site through the process described in Section 4.2, the event will be sent for adjudication with the available documentation.
4.3. CEC adjudication. The DCRI RECORD CEC physicians will adjudicate each suspected event using the prespecified end point criteria based on the preponderance of the evidence and clinical knowledge and experience. All events will be reviewed using the original RECORD Clinical Endpoints Committee definitions and the new definitions based on the FDA definitions (FDA Standardized Definitions for End Point Events in Cardiovascular Trials).
Potential events triggered from an adverse event term with no hospitalization or source documentation present will be reviewed by a single clinician (RECORD CEC coordinator or physician). The clinician will review the data present to determine whether or not a potential event occurred. If there are no data to support that an event occurred, a RECORD CEC Adjudication Form will be completed indicating no event. If there are data present to indicate that an event may have occurred, the event packet and data will be forwarded to phase I review for potential MI events and neurologist/phase II review for potential stroke events.
Phase I review is defined as a process whereby 2 physicians independently adjudicate each suspected event using the event criteria. The physicians will review each event using both the original RECORD Clinical Endpoints Committee definitions and the new definitions concurrently for all causes of death. Myocardial infarction events will be reviewed with a different strategy whereby 2 physicians will review each MI event independently using the original definitions, and a different set of 2 physicians will review the same MI event with the new definitions.
All events are assigned randomly to the RECORD CEC physician reviewers. The physicians will adjudicate suspected events using documentation from the CRF and available supporting source documentation. If there is insufficient documentation to determine whether an event occurred or to determine the specific classification, the CEC reviewer may ask for additional information or source documentation. In the event that 1 of the 2 reviewers requests additional information or source documentation, data or documents that have been obtained will be distributed to both reviewers.
If the phase I reviewers agree in their adjudication of the suspected event, the end point classification is complete. The final adjudication results are recorded on the RECORD CEC adjudication form and are entered into the DCRI RECORD CEC adjudication eCRF by the CEC clinical data assistant or designee. If the phase I reviewers do not agree regarding the classification of the suspected event, the event is adjudicated by phase II review.
Phase II review is a process whereby an Adjudication Committee meeting is organized comprising at least 3 faculty physicians. All disagreements from the phase I review process will be presented at the Adjudication Committee meeting of faculty members, and each event will be reviewed and a decision made by consensus of the phase II reviewers. If an event is classified as a "nonevent," the rationale for calling it a "nonevent" will be documented on the adjudication form.
If the committee requests additional information or source documentation, then the event will be reviewed once the documentation has been obtained. The final adjudication results are recorded on a RECORD CEC adjudication form and are entered into the DCRI RECORD CEC adjudication eCRF by the CEC clinical data assistant or designee.
All suspected stroke events will be classified based on original RECORD Clinical Endpoints Committee definitions and the new definitions. All suspected strokes will be adjudicated by one of the following methods (see CEC process flow):
• Phase II committee of at least 3 RECORD CEC physicians, including a neurologist • Initial review by neurologist, then review by phase II committee of at least 3 RECORD CEC physicians, including a neurologist • Initial review by neurologist, then review by phase II committee of at least 3 RECORD CEC physicians, excluding neurologist. If there is a disagreement between the neurologist and the phase II committee members, the event will be re-reviewed by a phase II committee, which will consist of at least 3 RECORD CEC physicians, including a neurologist.
The final adjudication results are recorded on a RECORD CEC adjudication form and are entered into the DCRI RECORD CEC adjudication eCRF by the CEC clinical data assistant or designee.
The DCRI CEC coordinator and chairperson will determine the need for and timing of meetings of the Phase II CEC Committee. The CEC physicians will have an initial face-to-face training meeting. In addition, the members of the CEC will have face-to-face meetings and/or conference calls to adjudicate events where there was a disagreement, to perform quality control (QC) review of events, and to adjudicate difficult events. During these meetings, the CEC committee will assess and refine processes and clarify the approach to review and adjudication of complex suspected end points. Minutes of the meetings will be taken by the CEC coordinator or designee. Minutes consist of a listing of events, events adjudicated, and attendance log.
4.4. Quality control 4.4.1. Quality control of the readjudication process. A random sample of adjudicated events will be reviewed for quality by the RECORD CEC group. The CEC QC plan is based on the historical strategy of including a 5% random sample of the total number of adjudicated events, ensuring a sample large enough to have the number = [square root (total number of cases)] + 1. The random sample(s) is(are) generated by the DCRI trial statistician. The sample of events is weighted more heavily toward the earlier part of the study. The initial random sample is generated after there are 50 adjudicated events in the database. Additional random samples will be generated after the first 100, 200, and 300 mortality events are adjudicated. The same approach will be used for the MI and stroke events. A sample will be generated after 100, 200, and 300 MI or stroke events are completed.
The events selected are reviewed by RECORD CEC physicians who are blinded to the original adjudicated result. The results of the QC review are compared with the original adjudication result. These results are summarized and reviewed by the RECORD CEC chairperson, and the findings were distributed to all committee members. A "major" discrepancy occurs when there is a disagreement as to whether an event did, or did not, occur. A "minor" discrepancy occurs when there was agreement on whether an event occurred, but disagreement on the date, time, type, or evidence. Potential actions based on the results of the QC review include continuing the CEC process without modifications, readjudication of events via the CEC process, modifying the CEC process with additional QC review, and additional CEC reviewer training or removal/replacement of a CEC member per CEC chairperson. A summary report is generated by the CEC coordinator after each QC review with the findings detailed to the CEC chairperson/director. Decisions regarding the CEC process, including a recommendation of changing the original result to that of the QC review, are made based on the QC results. 4.4.2. Quality control of the manual trigger program. A random sample of the documents that were screened during the manual trigger procedures will be rescreened to ensure the quality of the manual procedures. The QC process will include having a RECORD CEC physician rescreen the same documents that were screened by the RECORD CEC coordinators using the following metrics:
• 5% of the documents screened by the CEC coordinator will be reviewed by a physician • 5% of manual triggers not previously reviewed in above QC effort will be reviewed by a physician • 5% of subjects not triggered for an end point event will be selected for above QC effo1rt
Event criteria
See Appendices C and D for event definitions.
Documentation
The following guidelines should be followed for retention of Clinical Endpoints Committee documents:
• CEC will maintain event packets for each suspected event, including query correspondence with site, source documents, and adjudication forms during the trial. Event packets will be collated by subject number and kept in a secure, locked file.
• At the end of the readjudication effort, the complete event packet, including CRF pages, adjudication forms, source documents, and queries, will be sent to the sponsor for archiving.
CEC process flow
See Figures 1 and 2 .
Appendix B. RECORD reevaluation CEC trigger specifications
This appendix provides the details and process of how subjects with suspected end point events, including death, stroke, and MI, will be identified for CEC review in the RECORD CEC Reevaluation Trial.
Suspected events for review will be identified (or "triggered") by an electronic and manual review of the clinical data captured on the CRF. This initial set of "triggers" described in this document are based on extensive review of the protocol, CRF, and incorporation of CEC experience in prior trials. However, the development of clinical trial triggers is best viewed as an iterative process. If potential changes in the triggers are identified after cases have been reviewed, the triggers may be revised during the course of the trial with input from the clinical leadership, data management, and statistical teams as appropriate. Table IV ).
• Trigger for Stroke event if Invasive Cardiovascular Procedure/Amputation Form specifies the type of procedure as Surgical or Nonsurgical and the artery indicated is Carotid.
Electronic data listings
The following data listing has been electronically extracted from the database to identify potential events. Each data point listed will be screened by a RECORD CEC clinical trial coordinator to determine if the potential event requires CEC adjudication. Documentation that the data have been screened will be maintained on the Data Listing spreadsheet, along with the CEC trigger number, for the potential events sent for CEC adjudication.
• Serious Adverse Experiences deleted from database • Serious Adverse Experiences changed in the database • Abnormal ECGs and AE/SAE with onset date ± 14 days of ECG date • Hospitalization and AE/SAE with onset date ± 14 days of hospital admission date • Patients who started new cardiac medications (thrombolytics, intravenous IIb/IIIa inhibitors, and intravenous heparin) during the study • Patients who withdrew from Randomized Treatment phase of the study because of safety risk, admittance to a long-term health care facility, or other reason • Patients who withdrew completely from study and specified "other" reason
Manual triggers
The RECORD CEC clinical trial coordinators will perform a manual review of paper documents for each subject to identify potential events. Documentation that the paper sources were manually screened will be maintained via spreadsheet listing all enrolled subjects. Paper sources that the CEC coordinators will review include, but are not limited to, the following: Cardiovascular death shall be defined as any death for which an unequivocal noncardiovascular cause cannot be established. Cardiovascular death will include death after heart failure, death after acute MI, sudden death, and death due to acute vascular events. Deaths that are due to unknown causes (and therefore cannot be categorized into the categories listed below) will be classified as "unknown deaths" but will be counted as cardiovascular deaths for the analysis of the "primary end point." 1.1. Death after heart failure. This is defined as death due to the onset and progression of symptoms defining definite heart failure (as listed in the present charter). 1.2. Death after MI. This is defined as death within 30 days after acute MI. 1.3. Sudden death. This is defined as death due to one of the following reasons:
• within 1 hour after onset of new symptoms • witnessed death, without new symptoms occurring within 72 hours preceding death • cardiac arrest followed by death within 30 days even if temporarily recovered • unwitnessed death in the absence of new symptoms* 1.4. Death due to acute vascular events. This is defined as death due to aortic dissection, aortic aneurysm, pulmonary embolism, stroke, or any other vascular cause.
Myocardial Infarction Shock hemorrhagic * The premise for the death to be adjudicated in this category is that it is known that the patients did not have any signs or symptoms 24 hours before the death occurred; otherwise, it will constitute a death of unknown cause. Secondary stroke events resulting from blood diseases (eg, leukemia, polycythemia vera), as well as stroke symptoms from brain tumors or brain metastases, should be excluded. Secondary stroke caused by trauma and other disorders (eg, metabolic disturbance) or peripheral lesion that could cause a localizing neurologic deficit or coma should also be excluded.
Definite focal signs:
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Appendix D. FDA end point definitions
Death
The determination of the specific cause of cardiovascular death is complicated by the fact that we are particularly interested in one underlying cause of death (acute MI [AMI]) and several modes of death (arrhythmia and heart failure/low output). It is noted that heart attack-related deaths are manifested as sudden death or heart failure, so these events need to be carefully defined.
Cardiovascular death includes death resulting from an AMI, sudden cardiac death, death due to heart failure, death due to stroke, and death due to other cardiovascular causes, as follows:
1. Death due to Acute MI refers to a death by any mechanism (arrhythmia, heart failure, low output) within 30 days after an MI related to the immediate consequences of the MI, such as progressive congestive heart failure (CHF), inadequate cardiac output, or recalcitrant arrhythmia. If these events occur after a "break" (eg, a CHF-and arrhythmia-free period of at least a week), they should be designated by the immediate cause, although the MI may have increased the risk of that event (eg, late arrhythmic death becomes more likely after an AMI 
General considerations
• A subject seen alive and clinically stable 12 to 24 hours before being found dead without any evidence or information of a specific cause of death should be classified as "sudden cardiac death." Typical scenarios include the following:
• Subject well the previous day but found dead in bed the next day • Subject found dead at home on the couch with the television on
• Deaths for which there is no information beyond "Patient found dead at home" may be classified as "death due to other cardiovascular causes" or in some trials, "undetermined cause of death." Please see "Definition of Undetermined Cause of Death" section below for full details.
3. Death due to heart failure or cardiogenic shock refers to a death occurring in the context of clinically worsening symptoms and/or signs of heart failure without evidence of another cause of death and not after an AMI. Note that deaths due to heart failure can have various etiologies, including 1 or more AMIs (late effect), ischemic or nonischemic cardiomyopathy, or valve disease.
Death due to heart failure or cardiogenic shock should include sudden death occurring during an admission for worsening heart failure as well as death from progressive heart failure or cardiogenic shock after implantation of a mechanical assist device. New or worsening signs and/or symptoms of CHF include any of the following: a. New or increasing symptoms and/or signs of heart failure requiring the initiation of, or an increase in, treatment directed at heart failure or occurring in a patient already receiving maximal therapy for heart failure b. Heart failure symptoms or signs requiring continuous intravenous therapy or chronic oxygen administration for hypoxia caused by pulmonary edema c. Confinement to bed predominantly caused by heart failure symptoms d. Pulmonary edema sufficient to cause tachypnea and distress not occurring in the context of an acute MI or worsening renal function, or as the consequence of an arrhythmia occurring in the absence of worsening heart failure e. Cardiogenic shock not occurring in the context of an AMI or as the consequence of an arrhythmia occurring in the absence of worsening heart failure Cardiogenic shock is defined as systolic blood pressure is b90 mm Hg for greater than 1 hour, not responsive to fluid resuscitation and/or heart rate correction, and felt to be secondary to cardiac dysfunction and associated with at least one of the following signs of hypoperfusion:
• Cool, clammy skin or • Oliguria (urine output b30 mL/h) or • Altered sensorium or
Cardiogenic shock can also be defined if systolic blood pressure is b90 mm Hg and increases to ≥90 mm Hg in less than 1 hour with positive inotropic or vasopressor agents alone and/or with mechanical support.
Heart failure may have a number of underlying causes including acute or chronic ischemia, structural heart disease (eg, hypertrophic cardiomyopathy), and valvular heart disease. Where treatments are likely to have specific effects and it is likely to be possible to distinguish between the various causes, then it may be reasonable to separate out the relevant treatment effects. For example, obesity drugs such as fenfluramine (pondimin) and dexfenfluramine (redux) were found to be associated with the development of valvular heart disease and pulmonary hypertension. In other cases, the aggregation implied by the definition above may be more appropriate. 4 . Death due to stroke refers to death occurring up to 30 days after a stroke that is either caused by the stroke or caused by a complication of the stroke. • death results directly from the cancer; or • death results from a complication of the cancer (eg, infection, complication of surgery/chemotherapy/ radiotherapy); or • death results from withdrawal of other therapies because of concerns relating to the poor prognosis associated with the cancer.
Cancer deaths may arise from cancers that were present before randomization or which developed subsequently. It may be helpful to distinguish these 2 scenarios (ie, worsening of prior malignancy, new malignancy).
Suggested categorization includes common organ systems, hematologic, or unknown.
Definition of undetermined cause of death. Undetermined cause of death refers to a death not attributable to one of the above categories of cardiovascular death or to a noncardiovascular cause. Inability to classify the cause of death may be due to lack of information (eg, the only available information is "patient died") or when there is insufficient supporting information or detail to assign the cause of death. In general, the use of this category of death should be discouraged and should apply to a minimal number of patients in well-run clinical trials.
A common analytic approach for cause of death analyses is to assume that all undetermined cases are included in the cardiovascular category (eg, presumed cardiovascular death, specifically "death due to other cardiovascular causes"). Nevertheless, the appropriate classification and analysis of undetermined causes of death depend on the population, the intervention under investigation, and the disease process. The approach should be prespecified and described in the protocol and other trial documentation such as the end point adjudication procedures and/or the SAP.
Myocardial infarction 1. General considerations. The term MI should be used when there is evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia.
In general, the diagnosis of MI requires the combination of:
• evidence of myocardial necrosis (either changes in cardiac biomarkers or postmortem pathological findings); and • supporting information derived from the clinical presentation, ECG changes, or the results of myocardial or coronary artery imaging.
The totality of the clinical, ECG, and cardiac biomarker information should be considered to determine whether or not an MI has occurred. Specifically, timing and trends in cardiac biomarkers and ECG information require careful analysis. The adjudication of MI should also take into account the clinical setting in which the event occurs. Myocardial infarction may be adjudicated for an event that has characteristics of an MI but which does not meet the strict definition because biomarker or ECG results are not available.
Criteria for MI. a. Clinical presentation
The clinical presentation should be consistent with diagnosis of myocardial ischemia and infarction. Other findings that might support the diagnosis of MI should be taken into account because a number of conditions are associated with elevations in cardiac biomarkers (eg, trauma, surgery, pacing, ablation, congestive heart failure, hypertrophic cardiomyopathy, pulmonary ** Death due to a gastrointestinal bleed should not be considered a cardiovascular death.
embolism, severe pulmonary hypertension, stroke or subarachnoid hemorrhage, infiltrative and inflammatory disorders of cardiac muscle, drug toxicity, burns, critical illness, extreme exertion, and chronic kidney disease). Supporting information can also be considered from myocardial imaging and coronary imaging.
The totality of the data may help differentiate acute MI from the background disease process. b. Biomarker elevations
For cardiac biomarkers, laboratories should report an upper reference limit (URL). If the 99th percentile of the URL from the respective laboratory performing the assay is not available, then the URL for myocardial necrosis from the laboratory should be used. If the 99th percentile of the URL or the URL for myocardial necrosis is not available, the MI decision limit for the particular laboratory should be used as the URL. Laboratories can also report both the 99th percentile of the upper reference limit and the MI decision limit. Reference limits from the laboratory performing the assay are preferred over the manufacturer's listed reference limits in an assay's instructions for use.
Creatine kinase-MB (CK-MB) and troponin are preferred, but CK may be used in the absence of CK-MB and troponin. For MI subtypes, different biomarker elevations for CK, CK-MB, or troponin will be required. The specific criteria will be referenced to the URL. In many studies, particularly those in which patients present acutely to hospitals which are not participating sites, it is not practical to stipulate the use of a single biomarker or assay, and the locally available results are to be used as the basis for adjudication. However, if possible, using the same cardiac biomarker assay, and preferably a core laboratory, for all measurements reduces interassay variability. • Evidence that cardiac biomarker values were decreasing (eg, 2 samples 3-6 hours apart) before the suspected MI †
• ≥20% increase (and NURL) in troponin or CK-MB between a measurement made at the time of the initial presentation and a further sample taken 3 to 6 hours later † If biomarkers are increasing or peak is not reached, then a definite diagnosis of recurrent MI is generally not possible.
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b. Percutaneous coronary intervention-related MI Peri-PCI MI is defined by any of the following criteria. Symptoms of cardiac ischemia are not required.
Biomarker elevations within 48 hours of PCI:
• Troponin or CK-MB (preferred) N 3× URL and • No evidence that cardiac biomarkers were elevated before the procedure; OR • Both of the following must be true:
• ≥50% ‡ increase in the cardiac biomarker result • Evidence that cardiac biomarker values were decreasing (eg, 2 samples 3-6 hours apart) before the suspected MI 2. New pathological Q waves 3. Autopsy evidence of acute MI c. Coronary artery bypass grafting-related MI Peri-coronary artery bypass graft surgery (CABG) MI is defined by the following criteria. Symptoms of cardiac ischemia are not required.
Biomarker elevations within 72 hours of CABG:
• Troponin or CK-MB (preferred) N 5× URL and • No evidence that cardiac biomarkers were elevated before the procedure; OR • Both of the following must be true:
• ≥50% § increase in the cardiac biomarker result • Evidence that cardiac biomarker values were decreasing (eg, 2 samples 3-6 hours apart) before the suspected MI AND 2. One of the following:
• New, pathological Q waves persistent through 30 days • New, persistent, non-rate-related LBBB • ST-elevation MI • Additional subcategories may include the following the following: ‡ Data should be collected in such a way that analyses using ≥20% or ≥50% could both be performed. § Data should be collected in such a way that analyses using ≥20% or ≥50% could both be performed. Additional considerations. In trials involving patients with stroke, evidence of vascular central nervous system injury without recognized neurologic dysfunction may be observed. Examples include microhemorrhage, silent infarction, and silent hemorrhage. When encountered, the clinical relevance of these findings may be unclear. If appropriate for a given clinical trial, however, they should be precisely defined and categorized. The distinction between a transient ischemic attack and an ischemic stroke is the presence of infarction, not the transience of the symptoms. In addition to laboratory documentation of infarction, persistence of symptoms is an acceptable indicator of infarction. Thus, symptom transience should be defined for any clinical trial in which it will be used to distinguish between transient ischemia and infarction.
Types of MI
Appendix E. Statistical analysis plan, DCRI independent review, and readjudication of the RECORD trial, first phase (mortality) The hatched areas represent biomarker elevations below the decision limit used for these types of myocardial infarction. ⁎ Biomarkers are not available for this type of MI because the patients expired before biomarker determination could be performed.
† For the sake of completeness, the total distribution of biomarker values should be reported. The hatched areas represent biomarker elevations below the decision limit used for these types of MI.\
Scale Disability
0 No symptoms at all 1 No significant disability despite symptoms; able to carry out all usual duties and activities 2 Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance 3 Moderate disability; requiring some help, but able to walk without assistance 4
Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance 5
Severe disability; bedridden, incontinent, and requiring constant nursing care and attention 6 Dead 216.e16 Lopes et al 
Introduction
The readjudication/reanalysis of RECORD data is planned to be done in 2 phases. In the first phase, DCRI will screen RECORD data to identify deaths and classify each death according to cause (cardiovascular [CV], non-CV, or unknown). In the second phase, possible occurrences of nonfatal MI and nonfatal stroke will be identified and adjudicated.
This document describes planned statistical analyses of the first phase (mortality) only.
2.1. Background. The RECORD study was a longterm, open-label, randomized clinical trial in patients with type 2 diabetes, comparing the effects of the combination of rosiglitazone and either metformin or sulphonylurea with metformin plus sulphonylurea on cardiovascular end points and glycaemia. The results of RECORD have been published, 2 and study data have been submitted to the FDA.
Food and Drug Administration review of the RECORD trial raised questions about the "potential bias in identification of cardiovascular events due to the open-label design." 24 The FDA has requested an independent review of RECORD data and updated analyses for the specific end points all-cause mortality, cardiovascular mortality, major adverse cardiac end points (MACEs), and the individual components of MACE. GlaxoSmithKline has contracted DCRI to perform the independent review.
The Duke Clinical Research Institute plans to perform the review and readjudication in 2 phases, as described in DCRI Readjudication Protocol AVD115170 (Version 1.0; January 28, 2011). The first phase will focus on mortality (all-cause, cardiovascular, and noncardiovascular) end points, and the second phase will include analysis of the end points of MI (fatal and nonfatal), stroke (fatal and nonfatal), and MACE. Appendix I of Protocol AVD115170 contains the initial SAP describing the general approach to be taken in the analysis of the readjudicated data for both the first and second phases of the readjudication effort.
Analysis of first phase (mortality).
This document is the SAP for the analysis of mortality (allcause, cardiovascular, and noncardiovascular) end points assessed in the DCRI independent review and readjudication of the data from the RECORD study. It supersedes the SAP in Appendix I of Protocol AVD115170 and contains additional details of first phase analyses described in that document.
Objectives and operational overview
The independent data review and readjudication will be carried out in 2 phases. The first phase will consist of identification and review of all known deaths reported in the RECORD data package. The CEC will classify each death as cardiovascular, noncardiovascular, or unknown and identify the date of death. In addition, DCRI will use 1 or more algorithms to determine the date last known alive in patients not reported to have died. All persons involved in data review and adjudication will be blinded to randomized treatment arm and actual treatment administered.
In the second phase, CEC will review, based on predefined criteria, all suspected incidences of nonfatal MI or nonfatal stroke and determine whether an MI or stroke has actually occurred. For patients deemed to have had an MI or stroke, the CEC will identify the date of the event. For the end points of MI and stroke, DCRI will use 1 or more algorithms to determine the last known eventfree date in patients deemed not to have experienced an MI or stroke. All persons involved in data review and adjudication will be blinded to randomized treatment arm and actual treatment administered.
Analysis of the 2 phases will be stepwise, with the mortality results being reported first. This document describes the analysis of the first phase only.
The list of deaths identified from the first phase mortality review will be compared with the list originally reported in the RECORD trial results. If the first phase, mortality review has not identified all of the deaths originally reported in the RECORD trial results, additional screening may be necessary.
Upon completion of first-phase mortality screening and adjudication, DCRI will receive electronic data containing treatment group assignment information (randomized and actual treatment administered) from GSK and perform statistical analysis of the mortality results.
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Populations
All analyses will be performed on the 4447 patients included in the intent-to-treat (ITT) population in the original RECORD report.
Restriction of the analysis to a prespecified "per protocol" population (as a subset of the overall ITT population) is not intended. However, as described in Section 6, follow-up for time-to-event and event rate analyses may be limited to specific study phases defined to reduce the potential for bias in treatment effect estimation.
End points
The following end points will be summarized with timeto-event and event rate per 100 patient-year analyses. Note that this SAP describes the analysis of first phase only.
First phase (mortality)
1. All-cause mortality 2. CV mortality 3. Non-CV mortality Adjudication of deaths as CV, non-CV, or unknown cause will be done with 2 different methods, one using the original RECORD CEC definitions and one using contemporary definitions under development by FDA through the Standardized Data Collection for Cardiovascular Trials Initiative. Analyses of CV and non-CV mortality will be done for each method of adjudication.
End point status and end point dates for analyses of these end points will come from the DCRI CEC database containing the results of readjudication of identified cases. Last contact dates for vital status will be derived from the following sources:
1. RECORD database previously submitted by GSK to the FDA 2. Additional CRF data or documentation supplied to the DCRI by GSK 3. Individual patient information obtained from third party independent search, if conducted 4. Individual data received from any DCRI site queries conducted 6. Study phases and derivation of follow-up dates 6.1. Definition of study phases for mortality analysis. The initial DCRI SAP provided a general description (Appendix I, Protocol AVD115170, Version 1.0, Section 6) of plans for derivation of randomized treatment phase (RTP), CV follow-up (CVFU), and survival status follow-up (SSFU). The CVFU phase for a study subject involved regular examinations and telephone contacts to identify CV hospitalizations and key safety and efficacy outcomes, in addition to deaths. Study subjects who wished to leave the CVFU phase had the option to participate in the SSFU phase, which would require less frequent contact and would only assess vital status.
For this report, the follow-up period for the mortality analysis is based on all available follow-up where vital status could be reliably assessed and does not depend on whether follow-up occurred more frequently, as in the CVFU, or less frequently, as in the SSFU. For this reason, end of CVFU and end of SSFU phases will not be derived for the mortality analysis.
Derivation of the RTP is described in Section 6.3. 6.2. End of survival follow-up 6.2.1. Determination of death dates. Death dates will be identified by DCRI CEC as part of the adjudication process. When there is insufficient information to allow determination of the date of death, imputation will be done as described in Section 6.2.2 6.2.2. Imputation of dates. In general, incomplete survival followup and death dates will be imputed to the earliest date consistent with the recorded information. For example, if the only the month and year are reported, the imputed date will be the first of the month. If only the year is reported, the imputed date will be the first of the year. In cases where the year is not recorded, no algorithm is planned, and any imputation will be done on a case-by-case basis, taking into account other available dated information for that patient.
If, by using the above algorithm, an imputed death date precedes the date last known alive, the date of death in the analysis will be the date last known alive + 1 day. 6.2.3. Parsimonious approach to end of survival follow-up. The parsimonious approach to derivation of last follow-up dates for survival will require documented face-to-face contact at study visits where 1 or more of the following parameters were recorded on the VITALS module of the CRF:
The date of last follow-up for patients without a reported death will be the latest visit date where any of the above vital signs have been recorded. Patients who are reported to have died or who have values for any of the above parameters recorded on the VITALS panel after August 24, 2008 , will be considered to have completed survival follow-up (group I, Appendix Table VI) .
Based on preliminary review of RECORD electronic databases, approximately 85% of patients are in group I. Sections 6.2.4 to 6.2.6 describe approaches to obtaining additional vital status information and deriving additional follow-up from the existing RECORD data for the patients remaining in group II. 6.2.4. Survival follow-up for primary analysis. Additional follow-up information for patients in group II (Appendix Table VI ) will be used in the primary analysis of all-cause, CV, and non-CV mortality. There are 3 sources for the additional follow-up information: RECORD electronic database, independent third-party search, and DCRI internal review of CRFs and associated documentation. Use of these sources is described in Sections 6.2.4.1 to 6.2.4.3, respectively.
The date of last follow-up (for the primary analysis) for patients not reported to have died will be the latest of the dates described in Section 6.2.4.1 to 6.2.4.3. For patients who have died, the DCRI CEC will review available information to identify dates of death. In cases where the date of death cannot be determined imputation will be done as described in Section 6. on the independent third-party search, the death date will be determined as described in Section 6.2. Note: Primary analysis end of observation date is described in Boxes A, C, E, and F. For patients entering Box F, the last date alive is the latest faceto-face visit where vitals were collected.
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March 2011, after database finalization, and results were documented by insertion of relevant information in individual patient CRF packets. For patients shown to be alive later than the last face-to-face study visit and not reported to have died, the last observation date will be determined by the information from DCRI CRF review. The date of last follow-up will be the latest date known alive on or before December 31, 2008. For patients shown to be dead, the death date will be determined as described in Section 6.2.1. 6.2.5. Derivation of survival dates from test dates and reported patient events. The electronic database for patients with incomplete survival follow-up for the primary analysis will be screened for dates of specific patient visits or events which are later than last follow-up dates derived in Section 6.2.4. (Incomplete survival follow-up means a patient is not reported to have died, and the date last observed alive is before August 24, 2008) . The modules to be screened contain dates of electrocardiogram assessments, laboratory tests, microvascular (diabetes-related) end points, AEs, and fractures. In this approach to survival follow-up, the date last observed alive is defined as the later of
• the latest onset or event date found in these modules and • the date last observed alive derived using the method outlined in Section 6.2.4.
Analyses using follow-up derived from dates of electrocardiogram assessments, laboratory tests, microvascular (diabetes-related) end points, AEs, and fractures will not be considered primary and will be done only to assess the impact of incomplete follow-up documented from other sources. 6.2.6. Survival status follow-up and third-party searches within the RECORD study. For patients whose vital status after August 24, 2008 , cannot be determined by the method described in Sections 6.2.3 to 6.2.5, an additional method of deriving follow-up dates for mortality analysis will use dates obtained from survival status follow-up and thirdparty searches conducted as part of the RECORD study and included in the electronic database. With this method, the date last observed alive will be defined as the later of
• the date last observed alive based on telephone contact with the patient, health care worker, or friend/ relative/neighbor/other person or through third-party sources reported in the RECORD CRFs and • the date last observed alive derived using the method outlined in Section 6.2.4.
If application of this method increases observed study follow-up by at least 130 patient-years, then a sensitivity analysis for all-cause and CV mortality will be done. (130 patient-years is the approximate incremental amount of follow-up that would result in a reduction in estimated event rate of at least 0.0001, assuming 300 events and an initial value of 20,000 patient-years of follow-up.) 6.2.7. Flowchart describing derivations of end of survival follow-up.
6.3. Derivation of end dates for randomized treatment phase. The RTP is defined as the period of treatment with randomized add-on study medication (RSG, SU, or MET) and will include all visits from baseline until the earlier of study end or premature discontinuation from randomized study medication. For patients randomized to RSG, the end of RTP will be the date of last recorded dose of RSG. For patients randomized to SU/ MET, the end of RTP will depend on the background therapy stratum. End of RTP for patients in the background SU group will be defined as the date of the last recorded dose of MET. End of RTP for patients in the background MET group will be defined as the date of the last recorded dose of SU.
Last date of add-on study medication may be derived from 2 different sources on the CRF. One source is the "ADD-ON STUDY MEDICATION RECORD," which records dosing of each oral therapy administered in the intervals between visits. A second source is the reported "Date of final dose of add-on study medication," which may appear in 1 of 2 places on the CRF. These are as follows:
• "Date of final dose of add-on study medication" before leaving the randomized treatment phase from the STUDY CONTINUATION/WITHDRAWAL module or • "Date of final dose of add-on study medication" from the STUDY COMPLETION module.
The "ADD-ON STUDY MEDICATION RECORD" will serve as the primary source for deriving end of RTP. In cases where, due to missing or incomplete data, end of RTP cannot be derived from this part of the CRF, "Date of final dose of add-on study medication" will be used as the end of RTP. For patients in the ITT population who have no record of having received study drug, the end of RTP will be set to 1 day after randomization.
The end of RTP for patients who died while still receiving randomized treatment will be the CEC adjudicated date of death.
Analysis methods
Comparison of reported RECORD trial results
and DCRI independent readjudication. Comparisons of the results from original RECORD trial results and the DCRI independent readjudication results will be done only at the summary level. Integration of the original data and the DCRI-readjudicated data for estimation of treatment effect (RSG vs control arm) is not planned for this report.
7.2. Planned analyses of end points. The objectives of the statistical analyses will be the comparison of the RSG and MET/SU treatment groups and estimation of the treatment effect for the end points listed in Section 5. Reference date for time to event analysis will be date of randomization, with the exception of landmark analyses described in Section 7.3.4. For the end point of cardiovascular mortality, the primary analyses will classify deaths of unknown cause as cardiovascular.
For time-to-event analyses, the estimated treatment effect will be expressed in terms of the observed HR θ obs (= λ r,obs /λ c,obs ) and 2-sided 95% confidence limits, where λ r and λ c are the respective hazards for the RSG and MET/ SU combination groups.
The estimate of θ for each end point will be made using a Cox proportional hazard (PH) model, stratified by background treatment (MET or SU). The HR and 95% CI and 2-sided P values for the test of a difference from the null HR of 1 will be calculated. A test for interaction between treatment group and stratum will assess the homogeneity of the treatment effect across strata. The test for interaction may be considered significant if P ≤ .10. Secondary analyses will be done estimating θ with a Cox PH model, and 95% confidence limits, in each of the strata, MET or SU background treatment. If there is evidence of significant treatment group by stratum interaction (P ≤ .10), the within-stratum estimates of θ may be the most relevant.
Because the DCRI independent readjudication is retrospective in nature and was not planned as part of the RECORD trial, and also involves multiple end points, study phases, and methods for deriving censoring dates, formal testing for noninferiority lacks usual controls over type I and type II error.
Unadjusted Kaplan-Meier survival curves, HRs and 95% confidence limits, and incidence rates per 100 personyears are planned for all-cause mortality, CV mortality, and non-CV mortality using the survival primary analysis follow-up derivation described in Section 6.2.4.
This SAP describes a number of time-to-event analyses, which are considered exploratory, including sensitivity analyses and subgroup analyses. These analyses will be summarized with HRs (RSG/control) and 95% confidence limits and unadjusted Kaplan-Meier survival curves. A table will be presented showing median and mean followup time for each end of follow-up derivation method by treatment arm (RSG vs MET/SU) overall and by stratum.
When analyses of CV or non-CV mortality are done, results will be presented separately for the 2 methods used in adjudication of cause of death (original RECORD CEC definition and contemporary definitions under development by FDA through the Standardized Data Collection for Cardiovascular Trials Initiative.) 7.3. Additional elements of the report 7.3.1. Summaries of adjudication. Descriptive statistics will summarize the results of the selection of potential end points and the adjudication results, as shown in the following bullets. Summaries will be produced by treatment arm and for the total population.
• Number of patients triggered for adjudication • Data sources triggering cases selected for adjudication • Number (%) of deaths classified by cause (CV death, non-CV, cause unknown) and sufficiency of information (sufficient, insufficient), as defined by the original RECORD CEC and also by contemporary definitions under development by FDA through the Standardized Data Collection for Cardiovascular Trials Initiative. 7.3.2. On-treatment analyses. Two on-treatment analyses of allcause and CV mortality will be done, censoring patients alive on the last day of randomized treatment + 30 days, and the last day + 60 days. These analyses will be done using the survival primary analysis follow-up derivation described in Section 6.2.4, with cause of death adjudicated by the original RECORD CEC definitions and also contemporary definitions under development by FDA through the Standardized Data Collection for Cardiovascular Trials Initiative. 7.3.3. Subgroup analyses. Estimates of HRs (RSG/control) and 95% confidence limits will be computed for all-cause mortality and CV mortality for the following subgroups. No imputation will be done for subgroup variables with missing values on the electronic data sets.
• Demography
• Sex (male, female) To assess the impact of classifying deaths of unknown cause as cardiovascular, analyses of CV mortality will be repeated, classifying deaths of unknown cause as noncardiovascular (original CEC and contemporary definitions under development by FDA through the Standardized Data Collection for Cardiovascular Trials Initiative.) This analysis will use the primary method of survival follow-up as defined in Section 6.2.4.
To assess the impact of censoring date derivation, timeto-event and event rate analyses for overall mortality and cardiovascular mortality (contemporary definitions under development by FDA through the Standardized Data Collection for Cardiovascular Trials Initiative only) under the different sets of rules for deriving study phase end 216.e22 Lopes et al dates described in Sections 6.2.3, 6.2.5, and 6.2.6 (if follow-up is increased by at least 130 patient-years compared with the method used in Section 6.2.5) will be compared.
To assess a possible impact of Amendment 7, time-toevent and event rate analyses for overall and cardiovascular mortality (contemporary definitions under development by FDA through the Standardized Data Collection for Cardiovascular Trials Initiative only, primary method of survival status date derivation only, as in Section 6.2.4) will be compared.
• censoring all patients alive on February 27, 2006, the date of Amendment 7 • with a landmark analysis, assuming follow-up starts on February 27, 2006, and including all patients alive on that date
To assess the possible impact of a published interim report 23 of the RECORD trial, time-to-event and event rate analyses for overall and cardiovascular mortality (contemporary definitions under development by FDA through the Standardized Data Collection for Cardiovascular Trials Initiative only, primary method of survival status date derivation only, as in Section 6.2.4), will be compared.
• censoring all patients alive on June 5, 2007, the date of the interim report • with a landmark analysis, assuming follow-up starts on June 5, 2007 , and including all patients alive on that date
To assess the possibility of informative censoring, a Cox PH analysis of time-to-censoring will be done, where patients are counted as having events on the dates of censoring, whereas events are treated as "censored without event" for overall mortality and cardiovascular mortality (contemporary definitions under development by FDA through the Standardized Data Collection for Cardiovascular Trials Initiative only, primary method of survival status date derivation only, as in Section 6.2.4). A differential risk of censoring between RSG and control arms would indicate the possibility of informative censoring.
To assess the impact of selection of study cutoff date, analyses of all-cause and CV mortality will be done using August 24, 2008 , as the cutoff (instead of December 31, 2008) . This analysis will be done for cause of death adjudicated by contemporary definitions under development by FDA through the Standardized Data Collection for Cardiovascular Trials Initiative only, using the primary method of survival status date derivation, as in Section 6.2.4. The DCRI independent review of data from the RECORD trial will include derivation of follow-up dates for each of the 3 study phases, defined in the RECORD Reporting and Analysis Plan (Curtis PS, Crisp A, 2009, unpublished).
• Randomized treatment phase (RTP)
• CV follow-up (CVFU)
• Survival status follow-up (SSFU).
For each patient, the last date of RTP should be no later than the last date of CVFU, which should be no later than the last date of SSFU. The following description of study phases is copied from Section 8.5 of the RECORD Reporting and Analysis Plan.
"For the management of patient disposition and withdrawals, the following definitions will be used for tracking the various mechanisms available for follow-up:
• CV follow-up phase is the entire period of follow-up for CV events and comprises the following elements:
• Randomized treatment phase ║ is the period of treatment with add-on study medication (RSG, SU, or MET) and will include all visits from baseline until study end, or premature discontinuation from study medication, whichever is sooner.
• Post-randomised treatment CV follow-up phase is the period of follow-up from the time of premature discontinuation of study medication until study end, complete withdrawal, or move to survival status updates only, whichever is sooner. This phase comprises:
• CV outcomes phase (post-randomised treatment phase); • Tracking substudy: post-randomised treatment follow-up for subjects withdrawn before Protocol Amendment 7.
• Survival status follow-up is follow-up of survival status for subjects after withdrawal from CV followup phase."
As noted above, the RTP may be longer in the RSG arm than in the control arm. For the purpose of identifying study phases of comparable length in the 2 treatment arms, DCRI may also consider a randomized dualtreatment phase (RDTP), provided that the RECORD database contains sufficient information to derive end of dual treatment for most patients in the trial.
║ Note that, according to protocol, patients in the RSG-containing arms could add a third drug (SU for patients receiving MET + RSG or MET for patients receiving SU + RSG) in case of loss of glycemic control with the dual-drug treatment and could remain on treatment. Patients in the control arm (MET + SU), however, did not have the option of the addition of a third drug, in case of loss of glycemic control with dual-drug treatment, and would be withdrawn from randomized treatment. By design, the RTP would tend to be longer in the RSG-containing arm than in the control arm.
Because the length of the RTP, CVFU, and SSFU study phases may depend on patient experiences postrandomization, other phases may also be defined with the intent of making the length of the phases independent of postrandomization experience. Rules for derivation of additional phases will be documented in an addendum to the SAP, signed before code break.
Determination of the end of study phase dates is complicated by a number of factors including
• the overall complexity of the RECORD trial • the length of planned follow-up and usual reasons for loss to follow-up • treatment discontinuations resulting from loss of glycemic control • unscheduled visits at physician discretion to ensure regulation of glycemic control • lengthening of the RTP and CVFU following Amendment 7 (February 27, 2006) to achieve median follow-up of 6 years • multiple sources on the CRF from which to derive end of study phase dates, and • as typical in trials with long follow-up, uncertainty of visit and contact dates resulting in incomplete date fields on the CRF.
Owing to these factors, precise determination of end of study phase dates cannot be done for all patients, and in some cases, algorithms are required to provide approximations of the length of study phases. Approximation of the length of study phases for some patients may result in error in estimates of event rates or time-to-event analyses, and because RECORD was an open-label trial, there is also a potential for bias in treatment comparisons.
In its independent evaluation, DCRI intends to use at least 2 methods for deriving end of study phase dates. The first method will use a parsimonious approach, attempting to find as simple an algorithm as possible to define study phases. With the second method, DCRI will develop a more complex algorithm, taking into account the data patterns for specific patients for whom the parsimonious approach may give clearly inaccurate or conflicting results. If deemed necessary, additional approaches may also be considered. The parsimonious approach, due to its simplicity, may have less potential for bias at the expense of reduced precision in study phase definition for some patients. During derivation of end of study phase dates, DCRI will be blinded to treatment assignment and treatment actually administered. Details of the methods used in deriving end of study phase dates will be included in an addendum to this SAP, signed before code break.
For determination of follow-up dates for analysis of mortality, we will initially consider a parsimonious approach such as the one described below. It is anticipated that this initial approach will not identify valid follow-up dates for all patients, and we expect to make appropriate modifications in an attempt to determine accurate dates for the entire study population:
Appendix F. Statistical analysis plan, DCRI independent review, and readjudication of the RECORD trial, second phase (major adverse cardiac end points) 
Introduction
This analysis plan describes the second phase of the RECORD readjudication/reanalysis, focusing on the major adverse cardiac end points (MACE) and the components cardiovascular death, MI, and stroke. This document supplements the first-phase SAP, dated July 13, 2011, which described the methods used in the analysis of mortality. General information about the RECORD study can be found in the SAP dated July 13, 2011.
Objectives and operational overview
In the Re-adjudication Protocol AVD115170 for the Rosiglitazone Evaluated for Cardiovascular Outcomes and Regulation of glycaemia in Diabetes trial (RECORD) Report of the First Phase: Blinded readjudication of Allcause Mortality and Cardiovascular Mortality Final December 13, 2011, DCRI attempted to determine vital status at the end of the study for as many patients as possible, screened the data for all suspected deaths, and, for those patients determined to have died, classified the deaths according to cause (cardiovascular [CV], non-CV, or unknown). Time-to-event analyses were done for allcause, CV, and non-CV mortality, comparing event rates in the RSG and MET/SU arms.
In the second phase, CEC will use predefined criteria to review all suspected incidences of nonfatal MI or nonfatal stroke and judge whether an MI or stroke has actually occurred. For patients deemed to have had an MI or stroke, the CEC will identify the date of the event. DCRI will use 1 or more algorithms to determine the last known event-free date in patients deemed not to have experienced an MI or stroke. All persons involved in data review and adjudication will be blinded to randomized treatment arm and actual treatment administered.
Upon completion of first-phase mortality screening and adjudication, DCRI received electronic data containing treatment group assignment information (randomized and actual treatment administered) from GSK and performed statistical analysis of the mortality results. A lead statistician, a faculty/review statistician, a faculty cardiologist, and an editor from DCRI were unblinded to treatment group assignment and prepared the statistical analysis and study report of first-phase mortality data. The statistical analysis of second phase data will be done by separate lead and faculty/review statisticians who, during screening and adjudication of the data, have remained blinded to treatment group assignment and the results from analysis of mortality.
death, the date of the fatal MI will be the date of death. Classification of fatal stroke will be done similarly.
The MACE composite end point (number 1 in the above list) will include any additional data on CV death obtained after the database lock for the first-phase mortality report, including identification of previously unknown deaths, new information on patient follow-up, or updated classifications of cause of death.
An updated analysis of all-cause and CV mortality may be performed if additional deaths are found that occurred on or before December 31, 2008, or information has been obtained that results in a change of event classification (eg, CV death/no CV death), or a substantial amount of additional follow-up has been obtained. In particular, events adjudicated as nonfatal MIs or nonfatal strokes for patients not reported to have died may extend the survival follow-up periods for those patients, if the events occurred after the date last reported alive in the primary analysis in the first phase report. If performed, the updated analysis of all-cause and CV mortality will use the primary method of survival defined in Section 6.2.4 of the phase I SAP, dated July 13, 2011, incorporating the additional information found.
Adjudication of the events (nonfatal MI, fatal MI, nonfatal stroke, fatal stroke, and death from CV or unknown cause) will be done with 2 different methods, one using the original RECORD CEC definitions and one using contemporary definitions under development by FDA through the Standardized Data Collection for Cardiovascular Trials Initiative. Separate analyses will be reported for each adjudication method.
5.2. Additional composite end points. The following composite end points will be summarized with timeto-event and event rate per 100 patient-year analyses. Time-to-event and event rate analyses will be based on the first occurrence of any of the events in the composite.
1. First occurrence of all-cause mortality, nonfatal MI, or nonfatal stroke 2. First occurrence of cardiovascular (or unknown cause) mortality or nonfatal MI 3. First occurrence of all-cause mortality or nonfatal MI
Derivation of follow-up dates
In the RECORD trial, not all patients were followed up uniformly to the end of the study (final visits to be done August 24, 2008 , through December 24, 2008 ). The DCRI analysis considered patients whose end point status was known as of August 24, 2008 , to have completed followup. All events occurring through December 31, 2008, were included in the primary analysis.
Derivation of the follow-up period for nonfatal MI and nonfatal stroke will be done similarly to the derivation of the parsimonious approach to survival follow-up, described in Section 6.2.3, of the first-phase SAP (July 13, 2011). If a patient is determined to have at least 1 nonfatal MI, the last follow-up date for this end point is the date of the first occurrence of the nonfatal MI, and follow-up is considered uncensored. If a patient does not have a nonfatal MI, the last follow-up date for this end point is censored at the date of the last visit at which vital signs were recorded. A similar approach is used to derive follow-up dates for nonfatal stroke. Follow-up dates for nonfatal MI and nonfatal stroke are derived independently. For example, if a patient is determined to have a nonfatal MI, the date of the nonfatal MI will not be used to derive end of follow-up for nonfatal stroke.
For patients reaching the end point of MI (fatal or nonfatal), the last follow-up date is the date of the earliest event, and follow-up is uncensored. Patients without an MI are considered to have censored follow-up at the date of the last visit at which vital signs were recorded. A similar approach is used to derive follow-up dates for stroke (fatal or nonfatal). Follow-up dates for MI and stroke are derived independently.
Last follow-up date for patients experiencing at least 1 of the MACE events will be the date of the first occurrence of any of those events. Last follow-up date for patients who did not experience any MACE event will be the date of the last study visit at which vital signs were recorded.
Because some patients did not have regularly scheduled visits with vital sign recording through the end of the study, the follow-up period may be dependent on the occurrence of an event. As a result, follow-up periods may differ from one event to another for the same patient.
Analysis methods
Comparison of reported RECORD trial results
and DCRI independent readjudication. Comparisons of the results from the original RECORD trial and the DCRI independent readjudication will be done only at the summary level. Integration of the original data and the DCRI-readjudicated data for estimation of treatment effect (RSG vs control arm) is not planned for this report. Planning for this analysis, which involves interactions with DCRI, FDA, GSK, the RECORD Steering Committee, and the original RECORD CEC, is unlikely to be completed in time for inclusion into this report. See the DCRI Re-adjudication Protocol AVD115170 (January 28, 2011) Section 5.1, last bullet point. Additional analyses comparing patient level adjudication results from the original RECORD trial to the results of the DCRI independent readjudication may be performed at a later date and described separately.
7.2. Planned analyses of end points. The objectives of the statistical analyses will be the comparison of the RSG and MET/SU treatment groups and estimation of the treatment effect for the end points listed in Section 5. Reference date for time-to-event analysis will be date of • Baseline glycated hemoglobin (b7.4%, 7.4%-b7.8%, 7.8%-b8.4%, ≥8.4%) • Baseline CV drug use
• Angiotensin-converting enzyme inhibitors (yes, no)
• Statins (yes, no)
• Nitrates (yes, no)
• β-Blockers (yes, no) • By country 7.3.3. Sensitivity analyses. The following sensitivity analyses will be done to determine if the results from the DCRI independent readjudication of the RECORD trial are robust.
To assess the impact of classifying deaths of unknown cause as cardiovascular, analyses of MACE will be repeated classifying deaths of unknown cause as non-CV.
To assess the impact of insufficient information available for assessing whether or not an event occurred, analyses of MI, stroke, and MACE will be repeated classifying events with insufficient information as nonevents.
To assess possible impact of Amendment 7, time-toevent and event rate analyses for MI, stroke, and MACE will be compared:
• censoring all patients without event on February 27, 2006, the date of amendment 7 • with a landmark analysis, assuming follow-up starts on February 27, 2006, and including all patients who have not had an event before that date
To assess the possible impact of a published interim report 23 of the RECORD trial, time-to-event and event rate analyses for MI, stroke, and MACE, will be compared:
• censoring all patients without event on June 5, 2007 , the date of the interim report • with a landmark analysis, assuming follow-up starts on June 7, 2007 , and including all patients who have not had an event before that date
To assess the possibility of informative censoring, a Cox PH analysis of time-to-censoring, where patients are counted as having events on the dates of censoring, will be done, whereas events are treated as "censored without event" for MI, stroke, and MACE. A differential risk of censoring between RSG and control arms would indicate the possibility of informative censoring.
To assess the impact of selection of study cutoff date, time-to-event analyses of MI, stroke, and MACE will be done using August 24, 2008 as the cutoff (instead of December 31, 2008).
Other sensitivity analyses that will be considered include the following:
To examine the effect of a potential difference in followup periods among the end points of MI, stroke, and CV death, an analysis of MACE will be done taking into account interval censoring. In this analysis, major cardiovascular events determined by the occurrence of a CV or unknown cause of death after the date of the last face-to-face visit will be considered subject to interval censoring, and the HR between RSG and control arms will be estimated using the Weibull model, as described in Lindsey and Ryan. 24 In this analysis, the date of the MACE event will not be the date of the CV or unknown cause death; rather, it will be considered to occur between the date of the last face-to-face visit and the date of death, during a period when a nonfatal MI or stroke could have occurred without being reported. This analysis will use SAS PROC LIFEREG, and the model statement will be expressed as "MODEL (LOWER, UPPER) = {treatment arm indicator}/dist = weibull," where Because not all patients were followed up uniformly to the end of the RECORD trial, estimates of the amount of unobserved follow-up will be made, and the potential impact on MACE will be assessed. Unobserved follow-up will be calculated as the sum of time from the last visit at which vital signs were recorded to August 24, 2008 , for patients who did not have MACE. (Note that patients who were followed up to August 24, 2008 , would be considered to have completed the study follow-up.) Patients who had MACE would be considered to have no unobserved followup. We will simulate the occurrence of events between the date last observed without event and December 31, 2008, for patients who did not have MACE and were not followed up to August 24, 2008 . For each simulation run, the HR will be estimated from a data set containing the observed and simulated data. The distribution of the simulated outcomes will be described. The simulations will be done for a variety of assumed HRs, including the estimated HR from available data as well as HRs adverse to RSG (25%, 50%, 75%, and 100% increased risk).
To obtain an estimate of the HR accounting for baseline characteristics, a Cox PH model for the end points of MI, stroke, and MACE will be generated adjusting for variables described in Section 7.3.2 and possibly other clinically relevant baseline factors.
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